CLDI
Calidi Biotherapeutics, Inc.
NYSE AmericanUSDEQUITY
Healthcare
DELAYED
Strong sell
-63/100
Last price
1.01
▼ 0.01 (0.98%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.99
Prev close
1.02
Day high
1.02
Day low
0.99
Volume
47.22K
Market cap
$3.71M
P/E (TTM)
—
52W range
0.99 – 27.84
Day trading desk
Gap from prior close
-3.34%
Prior close 1.02
VWAP
1.01
+0.14% from price
Relative volume
0.18×
Quiet session
Session range
3.46%
0.99 – 1.02
Position in range
71%
Near session high
ATR (14D)
0.08
8.29% of price
Prior day high
1.07
PDH
Prior day low
1.00
PDL
Bid / ask spread
—
Quote not published
Session volume
47.16K
Avg 257.11K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.61%
-7.5%
1M
-25.19%
-26.6%
3M
-57.92%
-61.3%
6M
-74.55%
-89.5%
YTD
-94.60%
-108.6%
1Y
-95.95%
-111.6%
3Y
-99.98%
-181.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CLDI open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+3.47M
Net buying
Buy transactions
22
3.52M shares
Sell transactions
3
47.05K shares
Net transactions
+25
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
15.90K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Dec 12, 25 | CAMAISA ALLAN Director |
SELL | 850 | $1.24K | Indirect |
| Aug 21, 25 | POMA ERIC E. PH.D. Chief Executive Officer |
BUY | 25.00K | $50.00K | Direct |
| Aug 21, 25 | SCHOENECK JAMES A Director |
BUY | 75.00K | $150.00K | Direct |
| Aug 21, 25 | JACKSON ANDREW C Chief Financial Officer |
BUY | 2.50K | $5.00K | Direct |
| Aug 21, 25 | LEFTWICH SCOTT Director |
BUY | 125.00K | $250.00K | Direct |
| Dec 31, 24 | STEWART ALAN R Director |
— | 12.77K | — | Direct |
| Dec 31, 24 | LEFTWICH SCOTT Director |
— | 11.68K | — | Direct |
| Dec 17, 24 | CAMAISA ALLAN Chief Executive Officer |
SELL | 10.00K | $16.20K | Direct |
| Sep 26, 24 | CAMAISA ALLAN Chief Executive Officer |
STOCK | 70.16K | $80.68K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CAMAISA ALLAN |
Director | — | Sale |
JACKSON ANDREW C |
Chief Financial Officer | 2.50K | Purchase |
LEFTWICH SCOTT |
Director | 146.63K | Purchase |
POMA ERIC E. PH.D. |
Chief Executive Officer | 25.00K | Purchase |
SCHOENECK JAMES A |
Director | 84.51K | Purchase |
STEWART ALAN R |
Director | 28.98K | Stock Award(Grant) |
Fundamentals
Market cap$3.71M
Enterprise value$516.43K
Revenue (TTM)—
Gross profit—
EBITDA$-16.14M
Net income$-23.45M
EPS (TTM)$-36.47
Free cash flow$-10.02M
Total cash$4.07M
Total debt$1.94M
Book value / share$1.50
Shares outstanding3.68M
Float2.57M
Short % of float8.88%
Dividend yield0.00%
Beta (5Y)1.33
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.12
PEG ratio—
Price / sales—
Price / book0.67
EV / revenue—
EV / EBITDA-0.03
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-672.22%
Return on assets-134.79%
Debt / equity61.99
Current ratio1.68
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $45.00K | — | — |
| Operating revenue | $0 | $0 | $0 | $45.00K | — | — |
| Cost of revenue | — | — | $0 | $14.00K | $94.00K | — |
| Gross profit | — | — | $0 | $31.00K | $355.00K | — |
| Research & development | $9.74M | $8.88M | $13.01M | $7.26M | — | +9.7% |
| Selling, general & admin | $10.50M | $12.90M | $15.98M | $15.90M | — | -18.6% |
| Total operating expense | $20.19M | $21.59M | $26.11M | $23.16M | — | -6.5% |
| Operating income | -$20.19M | -$21.59M | -$26.11M | -$23.13M | — | +6.5% |
| Net interest income | -$207.00K | -$933.00K | -$3.75M | -$158.00K | — | +77.8% |
| Pre-tax income | -$20.05M | -$22.20M | -$29.20M | -$25.42M | — | +9.7% |
| Tax provision | $15.00K | $14.00K | $16.00K | $11.00K | — | +7.1% |
| Net income | -$19.91M | -$22.14M | -$29.22M | -$25.43M | — | +10.1% |
| Net income to common | -$25.58M | -$23.81M | -$29.22M | -$25.43M | — | -7.4% |
| Basic EPS | -95.20 | -571.20 | -3,327.36 | -1,359.66 | — | +83.3% |
| Diluted EPS | -95.20 | -571.20 | -3,327.36 | -1,359.66 | — | +83.3% |
| EBIT | -$19.84M | -$21.26M | -$28.13M | -$25.26M | — | +6.7% |
| EBITDA | -$18.19M | -$19.73M | -$26.88M | -$25.00M | — | +7.8% |
| Basic shares | 268.88K | 41.69K | 8.78K | 18.70K | — | +545.0% |
| Diluted shares | 268.88K | 41.69K | 8.78K | 18.70K | — | +545.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.60M | $9.59M | $1.95M | $372.00K | — | -41.6% |
| Cash & short-term investments | $5.60M | $9.59M | $1.95M | $372.00K | — | -41.6% |
| Total current assets | $6.26M | $10.23M | $4.30M | $786.00K | — | -38.8% |
| Property, plant & equipment | $2.46M | $3.80M | $5.34M | $1.09M | — | -35.2% |
| Total assets | $8.86M | $14.18M | $10.02M | $2.60M | — | -37.5% |
| Total current liabilities | $3.94M | $9.50M | $10.23M | $42.99M | — | -58.6% |
| Current debt | — | $3.18M | $807.00K | $5.42M | $5.00M | — |
| Long-term debt | $600.00K | $600.00K | $2.06M | — | — | 0.0% |
| Total debt | $2.56M | $7.04M | $7.24M | $5.99M | — | -63.6% |
| Total liabilities | $5.10M | $12.21M | $18.25M | $53.04M | — | -58.3% |
| Retained earnings | -$141.62M | -$121.72M | -$99.57M | -$70.36M | — | -16.4% |
| Shareholder equity | $3.76M | $1.53M | -$8.23M | -$50.44M | — | +145.0% |
| Working capital | $2.32M | $731.00K | -$5.93M | -$42.20M | — | +217.5% |
| Net tangible assets | $3.76M | $1.53M | -$8.23M | -$50.44M | — | +145.0% |
| Shares issued | 451.06K | 108.13K | 18.50K | 18.70K | — | +317.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$20.06M | -$22.21M | -$29.22M | -$25.43M | — | +9.7% |
| Depreciation & amortisation | $1.65M | $1.53M | $1.26M | $253.00K | — | +7.6% |
| Stock-based compensation | $2.11M | $2.96M | $4.81M | $6.14M | — | -28.7% |
| Change in working capital | -$4.74M | -$1.70M | -$6.24M | $3.57M | — | -179.3% |
| Operating cash flow | -$21.29M | -$19.69M | -$26.98M | -$13.21M | — | -8.1% |
| Capital expenditure | -$120.00K | -$16.00K | -$585.00K | -$428.00K | — | -650.0% |
| Investing cash flow | -$170.00K | -$16.00K | -$478.00K | -$494.00K | — | -962.5% |
| Share buybacks | — | — | — | — | $0 | — |
| Financing cash flow | $17.46M | $27.36M | $29.04M | $12.09M | — | -36.2% |
| Free cash flow | -$21.41M | -$19.71M | -$27.57M | -$13.64M | — | -8.6% |
| End cash position | $5.82M | $9.81M | $2.17M | $590.00K | — | -40.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $2.56M | $2.59M | $2.36M | $2.36M | $2.59M | — | -1.1% |
| Selling, general & admin | $1.59M | $1.60M | $2.11M | $2.69M | $3.07M | — | -0.5% |
| Total operating expense | $4.15M | $4.19M | $4.47M | $5.05M | $5.66M | — | -0.9% |
| Operating income | -$4.15M | -$4.19M | -$4.47M | -$5.05M | -$5.66M | — | +0.9% |
| Net interest income | -$35.00K | -$38.00K | -$42.00K | -$41.00K | -$52.00K | — | +7.9% |
| Pre-tax income | -$4.16M | -$4.10M | -$4.06M | -$5.17M | -$5.76M | — | -1.2% |
| Tax provision | $5.00K | $4.00K | -$2.00K | $10.00K | $4.00K | — | +25.0% |
| Net income | -$4.16M | -$4.11M | -$4.06M | -$5.15M | -$5.71M | — | -1.3% |
| Net income to common | -$4.16M | -$4.42M | -$4.06M | -$10.82M | -$5.71M | — | +5.8% |
| Basic EPS | -2.94 | -6.88 | — | -35.36 | -31.75 | -35.36 | +57.3% |
| Diluted EPS | -2.94 | -6.88 | — | -35.36 | -31.75 | -35.36 | +57.3% |
| EBIT | -$4.12M | -$4.07M | -$4.02M | -$5.13M | -$5.71M | — | -1.3% |
| EBITDA | -$3.68M | -$3.64M | -$3.60M | -$4.70M | -$5.30M | — | -1.2% |
| Basic shares | 1.42M | 644.25K | — | 306.69K | 180.00K | 141.06K | +119.8% |
| Diluted shares | 1.42M | 644.25K | — | 306.69K | 180.00K | 141.06K | +119.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.07M | $6.63M | $5.60M | $10.38M | $5.28M | — | -38.6% |
| Cash & short-term investments | $4.07M | $6.63M | $5.60M | $10.38M | $5.28M | — | -38.6% |
| Total current assets | $5.43M | $7.35M | $6.26M | $11.03M | $6.05M | — | -26.2% |
| Property, plant & equipment | $1.77M | $2.10M | $2.46M | $2.86M | $3.26M | — | -15.9% |
| Total assets | $7.20M | $9.59M | $8.86M | $14.03M | $9.35M | — | -24.9% |
| Total current liabilities | $3.24M | $3.84M | $3.94M | $5.19M | $5.35M | — | -15.6% |
| Current debt | — | — | — | $405.00K | $775.00K | $1.13M | — |
| Long-term debt | $600.00K | $600.00K | $600.00K | $600.00K | $600.00K | — | 0.0% |
| Total debt | $1.94M | $2.26M | $2.56M | $3.31M | $4.01M | — | -14.0% |
| Total liabilities | $4.07M | $4.66M | $5.10M | $6.83M | $7.28M | — | -12.6% |
| Retained earnings | -$149.89M | -$145.73M | -$141.62M | -$137.56M | -$132.42M | — | -2.9% |
| Shareholder equity | $3.13M | $4.93M | $3.76M | $6.92M | $1.76M | — | -36.5% |
| Working capital | $2.19M | $3.52M | $2.32M | $5.83M | $696.00K | — | -37.7% |
| Net tangible assets | $3.13M | $4.93M | $3.76M | $6.92M | $1.76M | — | -36.5% |
| Shares issued | 179.81K | 736.67K | 451.06K | 431.64K | 179.81K | — | -75.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$4.16M | -$4.11M | -$4.06M | -$5.18M | -$5.76M | — | -1.3% |
| Depreciation & amortisation | $438.00K | $426.00K | $423.00K | $427.00K | $407.00K | — | +2.8% |
| Stock-based compensation | $157.00K | $231.00K | $450.00K | $529.00K | $522.00K | — | -32.0% |
| Change in working capital | -$789.00K | -$617.00K | -$1.53M | -$113.00K | -$67.00K | — | -27.9% |
| Operating cash flow | -$4.35M | -$4.12M | -$5.04M | -$4.24M | -$4.88M | — | -5.8% |
| Capital expenditure | -$33.00K | -$5.00K | -$29.00K | -$27.00K | -$57.00K | — | -560.0% |
| Investing cash flow | -$33.00K | -$5.00K | -$79.00K | -$27.00K | -$57.00K | — | -560.0% |
| Dividends paid | — | — | — | $0 | $0 | $0 | — |
| Financing cash flow | $1.83M | $5.16M | $340.00K | $9.48M | -$469.00K | — | -64.5% |
| Free cash flow | -$4.39M | -$4.12M | -$5.07M | -$4.26M | -$4.94M | — | -6.4% |
| End cash position | $4.29M | $6.85M | $5.82M | $10.59M | $5.38M | — | -37.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Sep 2025 | -26.88 | -35.36 | -31.5% |
| Jun 2025 | -21.12 | -31.89 | -51.0% |
| Mar 2025 | -28.80 | -35.94 | -24.8% |
| Dec 2024 | -71.04 | -51.84 | +27.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.61%
Held by institutions1.00%
Institutions holding23
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.08
-6.39% from price
SMA 20
1.13
-10.55% from price
SMA 50
1.34
-24.37% from price
SMA 100
1.90
-46.83% from price
SMA 200
6.00
-83.17% from price
EMA 12
1.08
-6.84% from price
EMA 26
1.18
-14.36% from price
EMA 50
1.42
-29.12% from price
RSI (14)
32.6
Neutral
MACD (12,26,9)
-0.10
Hist 0.00
ATR (14)
0.08
8.29% of price
Realised vol 30D
67.4%
Annualised
Bollinger upper
1.29
20, 2σ
Bollinger lower
0.97
20, 2σ
50 / 200 cross
Death
1.34 vs 6.00
Trend bias
Below 200
-83.17%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.16
More volatile than market
Correlation to SPY
0.30
Loosely linked
Realised vol 30D
67.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-96.2%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.08
8.29% of price
Beta (reported)
1.33
5Y monthly, from filing
Short interest
Shares short
227.78K
Prior 313.26K
Change vs prior
-27.3%
Shorts covering
% of float
8.88%
Normal
% of shares out
8.81%
Against total outstanding
Days to cover
3.3
Liquid
Float
2.57M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 27, 24 | Ladenburg Thalmann | INITIATED | — | Buy |
| May 15, 24 | Baird | MAINTAINED | Outperform | Outperform |
| Mar 21, 24 | Baird | MAINTAINED | Outperform | Outperform |
| Mar 21, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 22, 23 | HC Wainwright & Co. | INITIATED | — | Buy |
| Oct 9, 23 | Baird | INITIATED | — | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:16
Split dateJul 31, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-25
Corporate Changes & Voting Matters
8-K · 2026-09-22
Periodic Financial Reports
10-Q · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-07-31
Corporate Changes & Voting Matters
8-K · 2026-07-16
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-18
Proxy Statements
DEFA14A · 2026-06-05
Headlines
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
GlobeNewswire · 12d ago
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
GlobeNewswire · 20d ago
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 29d ago
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire · 55d ago
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
GlobeNewswire · 72d ago
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
GlobeNewswire · 78d ago
Calidi Biotherapeutics to Effect 1-for-16 Reverse Stock Split
MT Newswires · 79d ago
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
GlobeNewswire · 79d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.